China's Giant Biogene raises about $301 million in Hong Kong share sale, term sheet shows
16/04/2025 23:12
SYDNEY, April 17 (Reuters) - China's Giant Biogene has raised about $301 million in a Hong Kong top up placement, according to a term sheet seen by Reuters. The company sold 35 million shares at HK$66.65, a 9.5% discount to Giant Biogene's closing price on the Hong Kong Stock Exchange on Wednesday, the term sheet showed. The final price was at the bottom end of the price range flagged to investors when the deal launched. (Reporting by Scott Murdoch; Editing by Leslie Adler) ((Scott.Murdoch@thomsonreuters.com;))
Recent news on Giant Biogene Holding
See all newsGiant Biogene's profit drops on higher distribution expenses
Brief: Giant Biogene Says Cross-Linked Recombinant Collagen Implant Receives China Medical Device Registration Certificate
Brief: Giant Biogene To Distribute Final Dividends Of Rmb0.5390 Per Share
Brief: Giant Biogene's Unit Received NMPA Medical Device Registration Certificate For Recombinant Collagen, Sodium Hyaluronate Solution
HK-listed Giant Biogene jumps on share buyback plan